Targeted red and near‑infrared light, often called photobiomodulation or red‑light therapy, is now commonly offered in clinics, sports facilities and to consumers.

Studies suggest it can speed wound healing, reduce some types of pain and help athletes recover after exercise. Yet uncertainty about the best devices, doses and long‑term effects, together with limited access in public health systems, means the therapy remains promising rather than routine care.

What is photomodulation?

Photobiomodulation (PBM) delivers low‑power light in the red (about 600–700 nm) and near‑infrared (about 700–1,100 nm) ranges. This is different from surgical or ablative lasers because the light is non‑thermal and intended to alter cell behaviour rather than cut tissue.

Over the past two decades researchers have tested PBM in laboratory experiments, animal models and human trials for applications that include wound healing, musculoskeletal pain, rehabilitation, sleep and metabolic measures.

PBM is already recommended for a few clinical uses. For example, international expert groups support PBM to prevent or treat radiation dermatitis and oral mucositis in people receiving cancer treatment. Outside those specified uses, practice varies widely in both clinical and consumer settings.

What new research or evidence shows

Recent systematic reviews and randomised trials published between 2022 and 2026 have strengthened evidence for several specific outcomes while also highlighting important limits.

Human trials and pooled analyses indicate that PBM can accelerate the closure of chronic wounds, improve scar quality and reduce the severity of radiation‑related skin and mucosal damage when used with validated parameters. Meta‑analyses of athletes and exercise studies have found that pre‑ or post‑exercise PBM is associated with faster recovery of strength, lower blood markers of muscle damage such as creatine kinase, and reduced perceived muscle soreness at 72 and 96 hours.

Reviews of chronic pain studies report moderate benefits in knee osteoarthritis and some tendinopathies; some fibromyalgia trials show larger improvements, though the certainty of those findings is mixed.

Controlled trials in shift workers and related settings suggest that carefully timed light exposure can modestly increase total sleep time and sleep efficiency.

Small randomised trials and meta‑analyses have reported modest reductions in body mass index, weight and cholesterol after abdominal PBM in people with obesity, but those metabolic findings remain preliminary and come from a limited evidence base.

How it works (mechanism explained)

PBM’s principal cellular target is the mitochondrion, the structure that produces most of a cell’s chemical energy. Chromophores within mitochondria, mainly cytochrome c oxidase, absorb photons in the red and near‑infrared bands.

This absorption can increase mitochondrial membrane potential and ATP production, giving cells more usable energy. Photons can also trigger photodissociation of nitric oxide from mitochondrial complexes; this process can restore respiration and increase local nitric oxide availability, which in turn improves microcirculation and tissue oxygenation.

A transient, dose‑dependent rise in reactive oxygen species follows in many settings; rather than causing damage, this short‑lived rise acts as a signalling event that activates cell survival, repair and antioxidant pathways.

PBM also appears to downregulate pro‑inflammatory signalling pathways such as NF‑κB and to stimulate tissue‑remodelling processes including collagen synthesis and new blood‑vessel formation.

Responses typically follow a biphasic pattern: low to moderate doses stimulate cellular repair, while too little or too much light produces less benefit.

How strong the evidence is

The strength of evidence differs by indication. For radiation‑related oral mucositis and dermatitis in oncology settings, and for some wound‑healing applications, the evidence is relatively robust and supported by clinical guidelines when standard protocols are followed.

For musculoskeletal pain and athletic recovery the evidence is moderate: meta‑analyses report benefits, but trials vary in methods, device settings and sample size, which reduces certainty.

For metabolic outcomes, transcranial PBM for cognition and broader sleep applications the evidence is preliminary; these findings are based on small trials, pilot studies or animal experiments and need confirmation in larger, well‑designed randomised controlled trials.

Across many studies the literature shows wide variation in wavelength, power density, energy delivered per site, frequency of sessions and total treatment duration. Small trial sizes, potential publication bias and inconsistent device quality in the consumer market further restrict confidence in generalising results.

What this means for patients or the public

For patients with guideline‑endorsed needs, such as preventing or treating oral mucositis during cancer therapy, PBM is an evidence‑based supportive option when delivered by trained clinicians using validated devices and parameters.

For people considering PBM for general wellness, weight loss or cognitive enhancement, current evidence does not support routine medical use.

Consumers should be cautious about low‑cost home devices because many are underpowered or use non‑optimal wavelengths; such devices may produce no benefit while leading to unnecessary expense.

Anyone with active cancer, photosensitive conditions, or taking photosensitising medication should consult a clinician before using PBM.

Treatments, prevention and policy implications

Therapeutic PBM is delivered either by clinician‑administered medical‑grade devices in clinics and hospitals or by consumer devices designed for home use. Clinic treatments are typically scheduled as a series of sessions with settings tailored to the clinical indication.

Policy issues include the need for clearer device regulation and labelling so that wavelength, power density and recommended energy per treatment site are stated and verifiable. Public payers and health services should consider covering PBM for indications supported by strong randomised controlled trial evidence.

Clinician training and inclusion of PBM protocols in clinical guidelines will help ensure safe and effective delivery rather than leaving patients to use poorly validated consumer devices.

What remains unknown and what comes next

Key unanswered questions include the precise dosing parameters that produce the best outcomes for each condition, the long‑term safety profile across diverse patient groups and the real‑world effectiveness of PBM when deployed at scale in routine healthcare.

It is also unclear whether promising early findings for metabolic and cognitive outcomes will withstand larger trials. Ongoing research includes larger pragmatic trials, mechanistic work on transcranial PBM for brain health, and registered studies testing standardised dosing for musculoskeletal and metabolic indications.

Better device regulation, multi‑centre studies and standardized protocols will be critical to close current knowledge gaps.

Key perspectives

Photobiomodulation is a science‑based, low‑risk therapy with clear benefits in some clinical settings and encouraging signals in others.

For now it is best regarded as a useful adjunct in specific circumstances where evidence supports its use rather than as a universal remedy. Wider, reliable adoption will depend on stronger trials, clearer dosing standards and improved device regulation.

For patients and clinicians the sensible approach is cautious optimism: recognise the established benefits where they exist, avoid unproven uses, and press for better evidence and fair access so effective treatments reach those who need them.